MECHANISMS OF INTERRELATIONSHIP BETWEEN OBESITY AND DEVELOPMENT OF POLYCYSTIC OVARY SYNDROME

  2. 2025
  3. Issue 2,177
  4. MECHANISMS OF INTERRELATIONSHIP BETWEEN OBESITY AND DEVELOPMENT OF POLYCYSTIC OVARY SYNDROME

Tkachenko S. S., Rodynskyi O. G., Reshetnikova Y. Yu.

MECHANISMS OF INTERRELATIONSHIP BETWEEN OBESITY AND DEVELOPMENT OF POLYCYSTIC OVARY SYNDROME

Show/Download

About the author:

Tkachenko S. S., Rodynskyi O. G., Reshetnikova Y. Yu.

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

Polycystic ovary syndrome is becoming increasingly common nowadays, with one in ten women worldwide fac- ing this problem. Detecting this endocrinopathy is considered a difficult task, but this field is currently undergoing intensive development due to the percentage increase in prevalence and the danger of development, as the disease provokes the appearance of concomitant pathologies, including infertility, metabolic syndrome, obesity, impaired glucose tolerance, type 2 diabetes mellitus, cardiovascular risk, depression, obstructive sleep apnoea, endometrial cancer, etc. The aim of this study is to substantiate the influence of central and peripheral obesity on the onset of the disease. Adipose tissue secretes several biologically active substances – adipokines, for example, leptin, which has an inhibitory effect on insulin-induced ovarian steroidogenesis; adiponectin, which plays an essential role in the production of progesterone and oestrogen, ovulation and reduction of gonadotropin-releasing hormone secretion, including affects the secretion of luteinising hormone by the pituitary gland and triggers the secretion of oestradiol; chemerin, which can disrupt follicle-stimulating hormone-induced follicular steroidogenesis, and others. As we can see, tissue secretion has a direct impact on a woman's reproductive function. The lipid profile of adipose tissue can also change, affecting PCOS symptoms (primarily by acting on the hypothalamic-pituitary-ovarian axis) and the fur- ther development of the pathology. Understanding these changes, as well as the relationship between excess weight and ovarian dysfunction, will allow for a comprehensive approach to the creation of screening programmes and treatment standards, as well as preventive measures for patients with polycystic ovary syndrome.

Tags:

adipocytokines, dyslipidemia, insulin resistance, obesity, polycystic ovary syndrome

Bibliography:

  1. Yang J, Chen C. Hormonal changes in PCOS. The Journal of endocrinology. 2024;261(1):e230342.
  2. Zhabitska L. Polycystic ovary syndrome: individualized approach to treatment. Literature review. Reproductive endocrinology. 2020;54:89-94. DOI: https://doi.org/10.18370/2309-4117.2020.54.89-94.
  3. Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction (Cambridge, England). 2010;140(3):347- 64.
  4. Stener-Victorin E, Padmanabhan V, Walters KA, Campbell RE, Benrick A, Giacobini P, et al. Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome. Endocrine reviews. 2020;41(4):bnaa010.
  5. Ghafari A, Maftoohi M, Samarin ME, Sepideh Barani S, Banimohammad M, Samie R. The last update on polycystic ovary syndrome (PCOS), diagnosis criteria, and novel treatment. Endocrine and Metabolic Science. 2025;17:100228. Available from: https://www. sciencedirect.com/science/ article/pii/S2666396125000147.
  6.  Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://pubmed.ncbi.nlm.nih.gov/29083730/.
  7.  Gupta S, Rajput D, Sood R, Bhatia R. PCOS-induced Cancers: A Brief Insight on the Relevance of Androgen and Obesity. Letters in Drug Design & Discovery. 2024;21(19):4587-4596. DOI: 10.2174/0115701808335436241226051501.
  8. Zheng L, Yang L, Guo Z, Yao N, Zhang S, Pu P. Obesity and its impact on female reproductive health: unraveling the connections. Front Endocrinol (Lausanne). 2024;14:1326546.
  9. Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. The Journal of clinical endocrinology and metabolism. 2020;105(8):e2695-e2709.
  10. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clinical medicine insights. Reproductive health. 2019;13:1179558119874042.
  11. Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. International journal of molecular sciences. 2022;23(2):583.
  12. Rehman R, Sheikh A. Polycystic Ovary Syndrome. Amsterdam: Elsevier; 2024. Chapter, Interplay of adipocytokines with polycystic ovary syndrome; p. 33-42. Available from: https://www.sciencedirect.com/science/article/ abs/pii/B9780323879323000141.
  13. Aparupa A, Singh R. Adipose Tissue Dysfunction in PCOS. Journal of Endocrinology & Reproduction. 2024;27(4):241-251. DOI: 10.18311/jer/2023/34082.
  14. Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clinical endocrinology 2021;95(4):531-541. Available from: .
  15. Dağ ZÖ, Dilbaz B. Impact of obesity on infertility in women. Journal of the Turkish German Gynecological Association. 2015;16(2):111-117.
  16. Stefanakis K, Upadhyay J, Ramirez-Cisneros A, Patel N, Sahai A, Mantzoros CS. Leptin physiology and pathophysiology in energy homeostasis, immune function, neuroendocrine regulation and bone health. Metabolism. 2024;161:156056.
  17. de Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome. Human Reproduction. 2021;27(4):771-796. DOI: 10.1093/humupd/dmab004.
  18. Еngin A. Adiponectin Resistance in Obesity: Adiponectin Leptin/Insulin Interaction. Advances in Experimental Medicine and Biology. 2024;1460:431-462. DOI: 10.1007/978-3-031-63657-8_15.
  19.  Yang J, Lin M, Tian X, Li C, Wu H, Deng L, et al. Serum adiponectin level is negatively related to insulin resistance in women with polycystic ovary syndrome. Endocrine Connections. 2024;14(1):e240401.
  20. Abdalla MMI. Role of visfatin in obesity-induced insulin resistance. World Journal of Clinical Cases. 2022;10(30):10840-10851. DOI: 10.12998/wjcc.v10.i30.10840.
  21.  Bose C, Mukherjee B, Pramanik S, Saha C, Singhania P, Mondal A, et al. A High Chemerin: Adiponectin Ratio is Associated with Dysglycemia in Patients with the Polycystic Ovarian Syndrome (PCOS). Endocrine Practice. 2023;29(5):S6-S7.
  22. Corbould AM, Bawden MJ, Lavranos TC, Rodgers RJ, Judd SJ. The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. Int J Obes Relat Metab Disord. 2002;26(2):165-75.
  23. Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstetrics & gynecology science. 2013;56(3):137-142.
  24. Behl T, Sinhg S, Sharma N. Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases. London: Academic Press; 2024. Chapter, Role of inflammation, oxidative stress, and angiogenesis in polycystic ovary syndrome (PCOS): Current perspectives; p.459-485. Available from: https://www.sciencedirect.com/science/article/abs/pii/B97 80443135873000187.
  25. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Advances in clinical and experimental medicine: official organ Wroclaw Medical University. 2017;26(2):359-367.

Publication of the article:

«Bulletin of problems biology and medicine», Issue 2,177, 121-129 pages, index UDC 612.83:612.662.9:618.173-073.7/-076-085:615.2.1-092.9

DOI:

10.29254/2077-4214-2025-2-177-121-129

Issue 2,177
adipocytokines dyslipidemia insulin resistance obesity polycystic ovary syndrome
01.07.2025
Was this article helpful?
5
4

Leave a Reply

Your email address will not be published. Required fields are marked *


The reCAPTCHA verification period has expired. Please reload the page.